Net margin is calculated as Net Income divided by its Revenue. PhotoCure ASA's Net Income for the
three
months ended in Mar. 2026 was kr83.4 Mil. PhotoCure ASA's Revenue for the
three
months ended in Mar. 2026 was kr264.6 Mil. Therefore, PhotoCure ASA's net margin for the quarter that ended in Mar. 2026 was 31.53%.
The historical rank and industry rank for PhotoCure ASA's Net Margin % or its related term are showing as below:
OSL:PHO'
s Net Margin % Range Over the Past 10 Years
Min: -22.99 Med: -4.61 Max: 24.58
Current: 12.55
OSL:PHO's Net Margin % is ranked better than 72.38% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs OSL:PHO: 12.55
PhotoCure ASA (OSL:PHO) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
PhotoCure ASA Net Margin % Related Terms
PhotoCure ASA Net Margin % Historical Data
* Premium members only.
The historical data trend for PhotoCure ASA's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:PHO vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PhotoCure ASA's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PhotoCure ASA Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PhotoCure ASA's Net Margin % distribution charts can be found below:
* The bar in red indicates where PhotoCure ASA's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PhotoCure ASA (OSL:PHO) has a Net Margin % of 31.53% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on PhotoCure ASA and its competitors. According to the industry distribution chart, PhotoCure ASA ranks #264 out of 956 companies in the Drug Manufacturers industry, placing it in the top 27.6%.
Is PhotoCure ASA's Net Margin % too high?
PhotoCure ASA's current Net Margin % is 31.53%. The Drug Manufacturers industry median Net Margin % is 5.56. PhotoCure ASA's value of 31.53% is 467.1% above this industry median. Based on the distribution chart, PhotoCure ASA ranks #264 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, PhotoCure ASA has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PhotoCure ASA's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PhotoCure ASA ranks #264 out of 956 companies for Net Margin %. This puts PhotoCure ASA in the upper half of its industry. The industry median Net Margin % is 5.56. PhotoCure ASA's value of 31.53% is 467.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PhotoCure ASA's current Net Margin % of 31.53% is 467.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on PhotoCure ASA and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PhotoCure ASA's current Net Margin % is 31.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhotoCure ASA stock overvalued right now?
Based on GuruFocus' analysis, PhotoCure ASA (OSL:PHO) is currently considered Modestly Undervalued. The stock's GF Value™ is kr74.44, compared to a current price of kr60.80 — trading 18.3% below its estimated fair value. The current Net Margin % is 31.53% and 467.1% above the Drug Manufacturers industry median of 5.56. PhotoCure ASA's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For PhotoCure ASA (OSL:PHO), the current Net Margin % is 31.53% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PhotoCure ASA (OSL:PHO) Overvalued in 2026?
Based on GuruFocus' analysis, PhotoCure ASA stock appears to be undervalued.
The current stock price of kr60.80 is trading 18.3% below its estimated GF Value™ of kr74.44.
GuruFocus considers PhotoCure ASA to be Modestly Undervalued.
Key valuation signals for OSL:PHO:
Net Margin %: 31.53%
GF Value™: kr74.44 vs. price of kr60.80 (18.3% below fair value)
Industry Position: 467.1% above the Drug Manufacturers median (#264 of 956)
No single metric tells the full story. See the OSL:PHO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
77GF Score
Get the complete analysis for OSL:PHO
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:PHO has been successfully added to your 
